Highlights

  • CSL Limited (ASX:CSL) reported FY26 revenue of US$15.797bn, compared with US$15.558bn in FY25.
  • Underlying NPATA was approximately US$3.1bn, down 2% on a constant-currency basis.
  • Reported FY26 loss attributable to shareholders was US$2.579bn following restructuring and impairment charges.
  • Operating cash flow reached US$3.512bn; the full-year dividend was maintained at US$2.92 per share.

CSL Limited develops and supplies plasma-derived therapies, influenza vaccines and medicines for kidney disease and iron deficiency across international healthcare markets. Following its FY26 results and a broad operational review, CSL Limited (ASX:CSL) shares closed at AUD 196.78 on 27 October 2026, The company is implementing changes to its research portfolio, manufacturing efficiency and commercial organisation after recording substantial impairment and restructuring charges. Its 2026 annual general meeting also took place on 27 October.

Company Business

CSL Limited (ASX:CSL) operates three main businesses. CSL Behring focuses on plasma-derived and other specialty therapies, including immunoglobulins, treatments for bleeding disorders and medicines for rare diseases. Its operations depend on plasma collection, specialised manufacturing capacity, clinical development and distribution arrangements across multiple markets.

CSL Seqirus develops and supplies influenza vaccines and supports pandemic preparedness programs. CSL Vifor supplies medicines in iron deficiency and nephrology. The group serves patients in more than 120 countries and has manufacturing and office operations across Australia, Europe, North America and Asia. Each business is affected by different clinical needs, reimbursement arrangements, competitive pressures and production requirements.

Recent Development

In August 2026, CSL Limited (ASX:CSL) released its results for the year ended 30 June 2026, describing FY26 as a period of operational reset. Management outlined a restructuring program targeting organisational efficiency, research prioritisation and improved commercial execution. The FY26 results presentation disclosed US$176mn in realised cost savings, with some funds being reinvested in commercial and pipeline initiatives.

The company also reported a completed approximately AUD 1bn share buyback and maintained its annual dividend. CSL has identified plans for approximately US$1.5bn of investment in US manufacturing over five years, including expansion of plasma-derived therapy capabilities. Its annual report discussed immunoglobulin demand, uptake of newer rare-disease medicines and competition affecting the iron portfolio.

CSL held its 2026 annual general meeting on 27 October. A separate 26 October governance announcement addressed board succession, including Brian McNamee’s retirement and Gordon Naylor’s appointment as the next chair. Leadership transition and delivery of the operational program remain relevant to subsequent company communications.

Financial Performance and Sector Context

CSL Limited (ASX:CSL) recorded FY26 operating revenue of US$15.797bn versus US$15.558bn in FY25. Underlying net profit after tax and amortisation was approximately US$3.1bn, representing a 2% constant-currency decline. The statutory loss attributable to shareholders was US$2.579bn, compared with a US$3.002bn profit in FY25. The reported outcome reflected significant restructuring and impairment-related charges, rather than the performance of ongoing operations alone.

On the company’s segment reporting basis, CSL Behring generated US$11.387bn of FY26 revenue, CSL Seqirus US$2.031bn and CSL Vifor US$2.379bn. FY26 operating cash flow was US$3.512bn. The company maintained its total dividend at US$2.92 per share, with its final dividend announced at US$1.62 per share.

Sector conditions differ across these businesses. Immunoglobulin demand is influenced by treatment utilisation and supply capacity, while influenza-vaccine sales depend on seasonal vaccination rates and government purchasing. CSL Vifor faces generic competition in iron medicines. Product access, regulatory requirements and currency translation also influence reported results.

Risks to Consider

For CSL Limited (ASX:CSL), the principal operating risks include plasma collection and manufacturing costs, competitive pricing, changes in vaccine uptake and the ability to commercialise new treatments. The FY26 impairments highlight the financial consequences when earlier assumptions about product portfolios or assets change. Additional considerations include clinical and regulatory outcomes, generic competition, investment execution, foreign exchange movements and potential delays in capturing restructuring savings.

What to Watch Next

CSL Limited (ASX:CSL) has scheduled its H1 FY27 results for February 2027. Relevant disclosures will include Behring immunoglobulin volumes and margins, Seqirus vaccine performance, Vifor’s exposure to generic competition and the financial effect of restructuring measures. Progress on US manufacturing investment, product launches and the executive transition will provide further evidence of how the operating priorities are being implemented. FY27 commentary also points to Behring and Seqirus revenue growth while indicating continuing pressure in Vifor.

Key Insights

CSL Limited (ASX:CSL) entered FY27 after a year characterised by broadly stable revenue, material statutory charges and substantial operating cash generation. Its portfolio spans distinct therapeutic and vaccine markets, making segment-level outcomes particularly important. Upcoming results will clarify the trajectory of cash flow, operating efficiency, commercial execution and the effects of competition across its three businesses.